<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-9964 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-9964</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-9964</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-170.html">extraction-schema-170</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <p><strong>Paper ID:</strong> paper-235592578</p>
                <p><strong>Paper Title:</strong> Exploring of Classification Methods for Early Detection of Alzheimer’s Disease</p>
                <p><strong>Paper Abstract:</strong> : Alzheimer's disease (AD) is a degenerative brain disease, a common health problem in elderly pesople which causes decline in memory and affected on nerve cells. AD has different stages like mild congestive impairment (MIC) (early stage), moderate (middle stage), severe (late stage) it is essential to detect AD early in MIC, so that pre-emptive measures can be taken. Significant research was carried out over the past century to diagnose and detect this disease early. The objective of the article is provide a review evaluation and critical analysis of the recent research work done to early diagnosis of AD using Machine Learning Strategies.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e9964.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e9964.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neurodegeneration</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuronal damage / neurodegeneration in Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Progressive loss of neurons and synapses in brain regions supporting memory and cognition, producing the clinical syndrome called Alzheimer's disease (AD). Presented in the paper as the fundamental pathological process underlying AD and its impact on behaviour and basic functions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>neurodegenerative</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>General neuronal damage and progressive neurodegeneration affecting brain areas responsible for memory, executive function and other cognitive domains (paper does not specify molecular agents such as amyloid-beta or tau by name).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states AD is a degenerative brain disease and that neuronal damage impacts brain functions (clinical/observational basis). The authors cite literature indicating that AD is the most common cause of dementia and that early stages (MCI) can be clinically distinguished from healthy controls and very mild AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Paper notes there is no single definitive test that can prove an individual has AD and that determining the exact cause of a patient's dementia can be difficult clinically; no molecular-level causal proof is provided within this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>clinical assessment / neuroimaging / biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Detection relies on clinical/neuropsychological assessment and on biomarkers and imaging (CT, MRI, PET, SPECT) and database-derived MRI analysis (ADNI, OASIS) described in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>No disease-specific sensitivity/specificity numbers for 'neurodegeneration' per se are reported. The paper reports machine-learning classification performance on imaging-derived features (see separate ML entry): e.g., SVM accuracy reported as 97.6% (TP rate 0.976, FP rate 0.021) for a classification task, but the paper does not link these metrics to a validated clinical sensitivity/specificity for detecting in vivo neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / narrative summary of clinical and imaging-based detection approaches</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not applicable as a single empirical study in this paper; the paper references public imaging datasets (ADNI, OASIS) described elsewhere (OASIS: 416 subjects, ages 18–96, ~100 >60 with very mild to moderate AD).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Paper emphasizes lack of a single definitive diagnostic test, clinical difficulty distinguishing causes of dementia, and the need for earlier and more specific biomarkers/features; it does not provide molecular causal proof and highlights limitations of current clinical and imaging approaches.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9964.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e9964.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Genetic risk profiles</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Genetic risk profiling for Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Analysis of genetic risk factors (unspecified in this paper) as potential contributors to AD risk and as diagnostic/prognostic markers; discussed as part of biomarker strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Paper refers generally to 'genetic risk profiles' as factors analysed in Alzheimer's research; no specific genes (e.g., APOE) are named in the text.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states genetic risk profiles are analysed in the literature and lists them among several biomarker types that can play a role in diagnosis and prognosis (cites Dubois et al. and other studies).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Paper notes genetic profiling is 'costly and complex to measure' in large numbers of assessments; no contradictory genetic-association data are presented in the paper itself.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>genetic screening / risk profiling</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Genetic testing / profiling to identify alleles or genetic signatures associated with increased AD risk (no operational details or markers given in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / mention of prior studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Main limitation noted is cost and complexity for large-scale measurement; the paper does not provide validation metrics or discuss clinical utility or penetrance/interpretation issues.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9964.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e9964.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Other dementia etiologies</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular, Lewy body, and frontal-lobe related dementias (non-AD causes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Other neuropathological causes of dementia that must be distinguished from AD, including vascular dementia, dementia with Lewy bodies, and frontotemporal (frontal lobe) dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>vascular / synucleinopathy / frontotemporal</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Paper lists vascular causes, Lewy body disease, and frontal lobe (frontotemporal) disease as alternate causes of dementia distinct from AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper notes that AD accounts for roughly 50–60% of dementia cases and that other types (vascular, Lewy body, frontal lobe) make up remaining cases — standard epidemiological summary referenced.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No direct refuting evidence in the paper; rather the paper highlights diagnostic difficulty in clinically distinguishing these causes from AD.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>differential diagnosis via clinical assessment and imaging/biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Differentiation uses clinical presentation, neuropsychological testing and imaging/biomarkers (CT/MRI/PET/SPECT and other markers) though specific modalities for discriminating each type are not detailed in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / epidemiological summary</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Population-level estimates referenced (age-related prevalence increases), but no single study population is analyzed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Paper emphasizes diagnostic overlap and clinician challenges; lack of specific, definitive tests for underlying cause is noted as a limitation.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9964.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e9964.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroimaging</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroimaging biomarkers (CT, MRI, PET, SPECT)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Structural and functional brain imaging modalities commonly used as biomarkers in AD research and diagnosis; MRI data (from OASIS/ADNI) are specifically used/studied for machine-learning classification in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>neuroimaging (structural and functional)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CT and structural MRI (T1-weighted scans), FDG-PET and other PET/SPECT modalities are described as imaging biomarkers; the paper specifically uses and discusses MRI datasets (OASIS, ADNI) and cites studies that apply 18F-FDG PET with deep learning.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>For MRI-based classification tasks reported in the paper (machine-learning experiments reported via WEKA): SVM reported accuracy 97.6% with TP rate (sensitivity) 0.976 and FP rate 0.021 (implying specificity ≈ 0.979). Other classifiers from Table IV: Naive Bayes TP rate 0.914 FP rate 0.053; Logistic TP 0.93 FP 0.06; Random Forest TP 0.954 FP 0.04. The paper cautions these are classification metrics from ML experiments and does not claim they equate to validated clinical diagnostic sensitivity/specificity in population screening.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>computational classification experiments cited in paper; review of imaging studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Paper describes OASIS dataset (cross-sectional, 416 subjects, ages 18–96, ~100 subjects >60 clinically diagnosed with very mild to moderate AD) and references ADNI; however the paper does not explicitly state which dataset was used for its reported WEKA metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Paper notes that imaging and biomarker measures can be costly/complex, that there is no single definitive imaging test proving AD, and that ML-derived performance may depend on choice of features, dataset size and preprocessing; the authors call for improved feature selection and validation across larger and diverse cohorts.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9964.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e9964.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrospinal fluid (CSF) biomarker analysis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Analysis of cerebrospinal fluid constituents (e.g., proteins considered AD biomarkers) used to support diagnosis and staging of AD; mentioned in the paper and in cited literature as important but requiring careful interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>biomarker (CSF assay)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CSF assays measure biomarkers used in AD research and clinical evaluation (paper references studies and a 2019 paper 'Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease').</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>No numerical sensitivity/specificity are given in this paper; the paper references external work that develops decision-tree methods to interpret CSF biomarkers but does not reproduce performance metrics here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / citation of diagnostic-biomarker studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Paper notes interpretation of CSF biomarkers requires decision-support (cited), CSF measures can be complex to interpret, and broad measurement is costly; no consensus single CSF threshold/test is presented in the paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9964.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e9964.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuropsychological testing</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuropsychological and cognitive testing (clinical assessment)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Battery of cognitive tests and neuropsychological evaluation used in clinical diagnosis and to distinguish MCI and dementia; paper states modern neuropsychological testing underpins clinical AD diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>cognitive / clinical testing</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Clinical neuropsychological tests and cognitive assessments are used to diagnose dementia, classify MCI, and verify intellectual deficits (specific tests not listed in the paper).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>The paper does not provide sensitivity/specificity figures for cognitive tests; it states clinical diagnosis is possible via neuropsychological testing but can be limited by atypical presentations and clinician constraints.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>clinical diagnostic practice / review</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Paper highlights that many psychiatric/neurological disorders are diagnosed clinically and that low levels of clinical evaluation and diagnostic barriers can lead to under-diagnosis; cognitive testing alone may not identify etiology and can miss early or atypical cases.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9964.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e9964.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Machine-learning classifiers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Machine-learning classifiers for AD detection (SVM, Logistic Regression, Random Forest, Naive Bayes, CNN, DNN, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Supervised and unsupervised machine-learning methods applied to imaging and other biomarker data to classify subjects as AD, MCI, or healthy controls; the paper reviews many such approaches and reports comparative performance metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>computational classification / pattern recognition</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Algorithms include supervised models (SVM, Logistic Regression, Random Forest, Naive Bayes) and deep-learning approaches (CNNs, DNNs); they operate on features extracted from MRI and other modalities (structural features, texture, volumetric, hippocampal region, wavelet features).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper reports comparative classifier metrics (Table IV) derived using WEKA: SVM TP rate (sensitivity) 0.976, FP rate 0.021 (implying specificity ≈ 0.979), precision 0.976, recall 0.976, ROC area 0.979; reported SVM accuracy stated in text as 97.6%. Random Forest: TP 0.954 FP 0.04 precision 0.957 ROC area 0.999; Logistic: TP 0.93 FP 0.06 precision 0.935 ROC area 0.986; Naive Bayes: TP 0.914 FP 0.053 precision 0.909 ROC area 0.978. The paper emphasizes these are algorithmic classification metrics and does not equate them to clinical diagnostic validation.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>computational experiments / review of ML studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>The specific dataset used to produce the WEKA-derived metrics is not explicitly stated in the text; paper describes public datasets (OASIS: 416 subjects; ADNI referenced) used in the field, but the sample and preprocessing for the reported metrics are not detailed.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Authors list several limitations: need for selection of appropriate features for early detection, removal of redundant/irrelevant features, potential overfitting and generalizability concerns, dependence on dataset quality and size, and the fact that high ML accuracy on a dataset does not substitute for clinically validated diagnostic tests. They also note computational methods often require careful validation across heterogeneous populations.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain <em>(Rating: 2)</em></li>
                <li>Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics <em>(Rating: 2)</em></li>
                <li>The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Imaging and machine learning techniques for diagnosis of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-9964",
    "paper_id": "paper-235592578",
    "extraction_schema_id": "extraction-schema-170",
    "extracted_data": [
        {
            "name_short": "Neurodegeneration",
            "name_full": "Neuronal damage / neurodegeneration in Alzheimer's disease",
            "brief_description": "Progressive loss of neurons and synapses in brain regions supporting memory and cognition, producing the clinical syndrome called Alzheimer's disease (AD). Presented in the paper as the fundamental pathological process underlying AD and its impact on behaviour and basic functions.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "neurodegenerative",
            "cause_description": "General neuronal damage and progressive neurodegeneration affecting brain areas responsible for memory, executive function and other cognitive domains (paper does not specify molecular agents such as amyloid-beta or tau by name).",
            "evidence_for_cause": "Paper states AD is a degenerative brain disease and that neuronal damage impacts brain functions (clinical/observational basis). The authors cite literature indicating that AD is the most common cause of dementia and that early stages (MCI) can be clinically distinguished from healthy controls and very mild AD.",
            "evidence_against_cause": "Paper notes there is no single definitive test that can prove an individual has AD and that determining the exact cause of a patient's dementia can be difficult clinically; no molecular-level causal proof is provided within this paper.",
            "detection_method_type": "clinical assessment / neuroimaging / biomarkers",
            "detection_method_description": "Detection relies on clinical/neuropsychological assessment and on biomarkers and imaging (CT, MRI, PET, SPECT) and database-derived MRI analysis (ADNI, OASIS) described in the paper.",
            "detection_performance": "No disease-specific sensitivity/specificity numbers for 'neurodegeneration' per se are reported. The paper reports machine-learning classification performance on imaging-derived features (see separate ML entry): e.g., SVM accuracy reported as 97.6% (TP rate 0.976, FP rate 0.021) for a classification task, but the paper does not link these metrics to a validated clinical sensitivity/specificity for detecting in vivo neurodegeneration.",
            "study_type": "review / narrative summary of clinical and imaging-based detection approaches",
            "study_population": "Not applicable as a single empirical study in this paper; the paper references public imaging datasets (ADNI, OASIS) described elsewhere (OASIS: 416 subjects, ages 18–96, ~100 &gt;60 with very mild to moderate AD).",
            "controversies_or_limitations": "Paper emphasizes lack of a single definitive diagnostic test, clinical difficulty distinguishing causes of dementia, and the need for earlier and more specific biomarkers/features; it does not provide molecular causal proof and highlights limitations of current clinical and imaging approaches.",
            "uuid": "e9964.0"
        },
        {
            "name_short": "Genetic risk profiles",
            "name_full": "Genetic risk profiling for Alzheimer's disease",
            "brief_description": "Analysis of genetic risk factors (unspecified in this paper) as potential contributors to AD risk and as diagnostic/prognostic markers; discussed as part of biomarker strategies.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "genetic",
            "cause_description": "Paper refers generally to 'genetic risk profiles' as factors analysed in Alzheimer's research; no specific genes (e.g., APOE) are named in the text.",
            "evidence_for_cause": "Paper states genetic risk profiles are analysed in the literature and lists them among several biomarker types that can play a role in diagnosis and prognosis (cites Dubois et al. and other studies).",
            "evidence_against_cause": "Paper notes genetic profiling is 'costly and complex to measure' in large numbers of assessments; no contradictory genetic-association data are presented in the paper itself.",
            "detection_method_type": "genetic screening / risk profiling",
            "detection_method_description": "Genetic testing / profiling to identify alleles or genetic signatures associated with increased AD risk (no operational details or markers given in this paper).",
            "detection_performance": null,
            "study_type": "review / mention of prior studies",
            "study_population": null,
            "controversies_or_limitations": "Main limitation noted is cost and complexity for large-scale measurement; the paper does not provide validation metrics or discuss clinical utility or penetrance/interpretation issues.",
            "uuid": "e9964.1"
        },
        {
            "name_short": "Other dementia etiologies",
            "name_full": "Vascular, Lewy body, and frontal-lobe related dementias (non-AD causes)",
            "brief_description": "Other neuropathological causes of dementia that must be distinguished from AD, including vascular dementia, dementia with Lewy bodies, and frontotemporal (frontal lobe) dementia.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "vascular / synucleinopathy / frontotemporal",
            "cause_description": "Paper lists vascular causes, Lewy body disease, and frontal lobe (frontotemporal) disease as alternate causes of dementia distinct from AD.",
            "evidence_for_cause": "Paper notes that AD accounts for roughly 50–60% of dementia cases and that other types (vascular, Lewy body, frontal lobe) make up remaining cases — standard epidemiological summary referenced.",
            "evidence_against_cause": "No direct refuting evidence in the paper; rather the paper highlights diagnostic difficulty in clinically distinguishing these causes from AD.",
            "detection_method_type": "differential diagnosis via clinical assessment and imaging/biomarkers",
            "detection_method_description": "Differentiation uses clinical presentation, neuropsychological testing and imaging/biomarkers (CT/MRI/PET/SPECT and other markers) though specific modalities for discriminating each type are not detailed in the paper.",
            "detection_performance": null,
            "study_type": "review / epidemiological summary",
            "study_population": "Population-level estimates referenced (age-related prevalence increases), but no single study population is analyzed in this paper.",
            "controversies_or_limitations": "Paper emphasizes diagnostic overlap and clinician challenges; lack of specific, definitive tests for underlying cause is noted as a limitation.",
            "uuid": "e9964.2"
        },
        {
            "name_short": "Neuroimaging",
            "name_full": "Neuroimaging biomarkers (CT, MRI, PET, SPECT)",
            "brief_description": "Structural and functional brain imaging modalities commonly used as biomarkers in AD research and diagnosis; MRI data (from OASIS/ADNI) are specifically used/studied for machine-learning classification in the paper.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method_type": "neuroimaging (structural and functional)",
            "detection_method_description": "CT and structural MRI (T1-weighted scans), FDG-PET and other PET/SPECT modalities are described as imaging biomarkers; the paper specifically uses and discusses MRI datasets (OASIS, ADNI) and cites studies that apply 18F-FDG PET with deep learning.",
            "detection_performance": "For MRI-based classification tasks reported in the paper (machine-learning experiments reported via WEKA): SVM reported accuracy 97.6% with TP rate (sensitivity) 0.976 and FP rate 0.021 (implying specificity ≈ 0.979). Other classifiers from Table IV: Naive Bayes TP rate 0.914 FP rate 0.053; Logistic TP 0.93 FP 0.06; Random Forest TP 0.954 FP 0.04. The paper cautions these are classification metrics from ML experiments and does not claim they equate to validated clinical diagnostic sensitivity/specificity in population screening.",
            "study_type": "computational classification experiments cited in paper; review of imaging studies",
            "study_population": "Paper describes OASIS dataset (cross-sectional, 416 subjects, ages 18–96, ~100 subjects &gt;60 clinically diagnosed with very mild to moderate AD) and references ADNI; however the paper does not explicitly state which dataset was used for its reported WEKA metrics.",
            "controversies_or_limitations": "Paper notes that imaging and biomarker measures can be costly/complex, that there is no single definitive imaging test proving AD, and that ML-derived performance may depend on choice of features, dataset size and preprocessing; the authors call for improved feature selection and validation across larger and diverse cohorts.",
            "uuid": "e9964.3"
        },
        {
            "name_short": "CSF biomarkers",
            "name_full": "Cerebrospinal fluid (CSF) biomarker analysis",
            "brief_description": "Analysis of cerebrospinal fluid constituents (e.g., proteins considered AD biomarkers) used to support diagnosis and staging of AD; mentioned in the paper and in cited literature as important but requiring careful interpretation.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method_type": "biomarker (CSF assay)",
            "detection_method_description": "CSF assays measure biomarkers used in AD research and clinical evaluation (paper references studies and a 2019 paper 'Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease').",
            "detection_performance": "No numerical sensitivity/specificity are given in this paper; the paper references external work that develops decision-tree methods to interpret CSF biomarkers but does not reproduce performance metrics here.",
            "study_type": "review / citation of diagnostic-biomarker studies",
            "study_population": null,
            "controversies_or_limitations": "Paper notes interpretation of CSF biomarkers requires decision-support (cited), CSF measures can be complex to interpret, and broad measurement is costly; no consensus single CSF threshold/test is presented in the paper.",
            "uuid": "e9964.4"
        },
        {
            "name_short": "Neuropsychological testing",
            "name_full": "Neuropsychological and cognitive testing (clinical assessment)",
            "brief_description": "Battery of cognitive tests and neuropsychological evaluation used in clinical diagnosis and to distinguish MCI and dementia; paper states modern neuropsychological testing underpins clinical AD diagnosis.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method_type": "cognitive / clinical testing",
            "detection_method_description": "Clinical neuropsychological tests and cognitive assessments are used to diagnose dementia, classify MCI, and verify intellectual deficits (specific tests not listed in the paper).",
            "detection_performance": "The paper does not provide sensitivity/specificity figures for cognitive tests; it states clinical diagnosis is possible via neuropsychological testing but can be limited by atypical presentations and clinician constraints.",
            "study_type": "clinical diagnostic practice / review",
            "study_population": null,
            "controversies_or_limitations": "Paper highlights that many psychiatric/neurological disorders are diagnosed clinically and that low levels of clinical evaluation and diagnostic barriers can lead to under-diagnosis; cognitive testing alone may not identify etiology and can miss early or atypical cases.",
            "uuid": "e9964.5"
        },
        {
            "name_short": "Machine-learning classifiers",
            "name_full": "Machine-learning classifiers for AD detection (SVM, Logistic Regression, Random Forest, Naive Bayes, CNN, DNN, etc.)",
            "brief_description": "Supervised and unsupervised machine-learning methods applied to imaging and other biomarker data to classify subjects as AD, MCI, or healthy controls; the paper reviews many such approaches and reports comparative performance metrics.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method_type": "computational classification / pattern recognition",
            "detection_method_description": "Algorithms include supervised models (SVM, Logistic Regression, Random Forest, Naive Bayes) and deep-learning approaches (CNNs, DNNs); they operate on features extracted from MRI and other modalities (structural features, texture, volumetric, hippocampal region, wavelet features).",
            "detection_performance": "Paper reports comparative classifier metrics (Table IV) derived using WEKA: SVM TP rate (sensitivity) 0.976, FP rate 0.021 (implying specificity ≈ 0.979), precision 0.976, recall 0.976, ROC area 0.979; reported SVM accuracy stated in text as 97.6%. Random Forest: TP 0.954 FP 0.04 precision 0.957 ROC area 0.999; Logistic: TP 0.93 FP 0.06 precision 0.935 ROC area 0.986; Naive Bayes: TP 0.914 FP 0.053 precision 0.909 ROC area 0.978. The paper emphasizes these are algorithmic classification metrics and does not equate them to clinical diagnostic validation.",
            "study_type": "computational experiments / review of ML studies",
            "study_population": "The specific dataset used to produce the WEKA-derived metrics is not explicitly stated in the text; paper describes public datasets (OASIS: 416 subjects; ADNI referenced) used in the field, but the sample and preprocessing for the reported metrics are not detailed.",
            "controversies_or_limitations": "Authors list several limitations: need for selection of appropriate features for early detection, removal of redundant/irrelevant features, potential overfitting and generalizability concerns, dependence on dataset quality and size, and the fact that high ML accuracy on a dataset does not substitute for clinically validated diagnostic tests. They also note computational methods often require careful validation across heterogeneous populations.",
            "uuid": "e9964.6"
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "decision_tree_supports_the_interpretation_of_csf_biomarkers_in_alzheimers_disease"
        },
        {
            "paper_title": "A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain",
            "rating": 2,
            "sanitized_title": "a_deep_learning_model_to_predict_a_diagnosis_of_alzheimer_disease_by_using_18ffdg_pet_of_the_brain"
        },
        {
            "paper_title": "Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics",
            "rating": 2,
            "sanitized_title": "predicting_shortterm_mcitoad_progression_using_imaging_csf_genetic_factors_cognitive_resilience_and_demographics"
        },
        {
            "paper_title": "The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "the_predictad_project_development_of_novel_biomarkers_and_analysis_software_for_early_diagnosis_of_the_alzheimers_disease"
        },
        {
            "paper_title": "Imaging and machine learning techniques for diagnosis of Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "imaging_and_machine_learning_techniques_for_diagnosis_of_alzheimers_disease"
        },
        {
            "paper_title": "An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning",
            "rating": 1,
            "sanitized_title": "an_intelligent_alzheimers_disease_diagnosis_method_using_unsupervised_feature_learning"
        }
    ],
    "cost": 0.014056999999999998,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Exploring of Classification Methods for Early Detection of Alzheimer's Disease Exploring of Classification Methods for Early Detection of Alzheimer's Disease 5207 AUTHORS PROFILE
August 2019</p>
<p>G Stalin Babu 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Management, TekkaliA P 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>India S N 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Tirumala Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Rajeswara Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>G Stalin Babu 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>S 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Tirumala Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Rajeswara Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>G Stalin Babu 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Exploring of Classification Methods for Early Detection of Alzheimer's Disease Exploring of Classification Methods for Early Detection of Alzheimer's Disease 5207 AUTHORS PROFILE</p>
<p>International Journal of Engineering and Advanced Technology (IJEAT)
6August 201910.35940/ijeat.F8215.088619Revised Manuscript Received on August 05, 20195206 Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619/2019©BEIESP Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619/2019©BEIESP Research Scholar at JNTUK Kakinada in Department of CSE ,working as Assistant Professor in Aditya institute of technology and management , His area of research are image processing. Dr. S.N. Tirumala Rao, M.Tech ., Ph.D . He is working as Professor and Head of the Department of CSE, NarasaraoPeta Engineering College, Narasaraopet, Guntur(AP)-India. His Areas of research are Data Mining, Multi-Core and Parallel Programming and Computer Networks. He Published more than 20 National and International Journals and organized several National and International Conferences. Books Published: Advanced Unix Programming HI-Tech Publisher. Dr.R.Rajeswara Rao, Professor, Dept of CSE, JNTUK University college of Engg. Vizianagram(AP), India. His Areas of Interest: Speech Processing, Pattern Recognition, and Cloud Computing. He Published papers in several National and International Journals and also organized several National and International Conferences.Alzheimer diseaseClassificationMachine Learning
Abstract: Alzheimer's disease (AD) is a degenerative brain disease, a common health problem in elderly pesople which causes decline in memory and affected on nerve cells. AD has different stages like mild congestive impairment (MIC) (early stage), moderate (middle stage), severe (late stage) it is essential to detect AD early in MIC, so that pre-emptive measures can be taken. Significant research was carried out over the past century to diagnose and detect this disease early. The objective of the article is provide a review evaluation and critical analysis of the recent research work done to early diagnosis of AD using MachineLearning Strategies.</p>
<p>I. INTRODUCTION</p>
<p>Alzheimer's disease (AD) is a brain degenerative disease. It is a effect on human thoughts and work. It is also caused by the other diseases and conditions. Like a decline in memory, effected on nerve cells. Neuronal damage in Alzheimer's disease consequently impacts parts of the brain that allow an person to perform general body activities such as walking, swallowing eating etc [22]. Dementia is a term describing a variety of disorders, and there are many various types of dementia, such as Alzheimer's disease, dementia with Lowy bodies and vascular dementia, and others. Dementia of the type (AD) of Alzheimer's disease is by far the most common cause of dementia. It is widely acknowledged that early detection of dementia can lead to more effective intervention and morbidity constraint Their research concludes that people who encounter MCI criteria can be differentiated from healthy control subjects and those with very mild Alzheimer's disease. It appears that this group of subjects is a clinical entity that can described for therapy measures.</p>
<p>To date, most mental disorder types have been diagnosed based on clinical observation. In specific, those include recognition of disorders that tend to cluster together, the timing of disease appearance and their tendency to cure, persist or be chronic. Currently there are no effective and efficient diagnostic tools not available to detect Alzheimer's. Boise et al. acknowledge prior research of low levels of clinical evaluation and diagnosis and conclude a possible explanation for this in the originality of the symptoms of dementia associated with the constraints encountered by physicians in their clinical practice. Through modern neuropsychological and cognitive testing, Alzheimer's disease is clinically diagnosed and other evidence of intellectual deficiency is verified [25]. According to Dubois et al., in addition to the clinical measures, the recommendations for the diagnosis of Alzheimer's disease accentuate the role that distinct biomarkers can perform. Like Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed tomography (SPECT) etc., Genetic risk profiles are analysed although they are costly and complex to measure to large amounts of evaluations. There is no specific test that can prove whether a individual has Alzheimer's disease or not [23]. While physicians always can evaluate whether an person has dementia, the actual cause can be difficult to determine. Alzheimer's disease immunology and risk parameters make up 50% to 60% of all dementia situations in the modern world today. Some of the other causes of dementia are vascular, lewd body and frontal lobe.The incidence of dementia rises with age, from 1% in 60-64 to 24-33% in those 85 years of age or elder. Around 24.3 million persons suffered from dementia in 2001, which is predicted to double every two decades as life expectancy also rises to 81.1 million in 2040. Western Europe, the USA and China are the nations and regions of the globe that are most impacted.By 2040, 55.7% of the total population impacted will be ho me to these nations and regions</p>
<p>II. ALZHEIMER'S DIESES</p>
<p>A. Alzheimer's early signs and symptoms [20]</p>
<p> Memory loss that disrupts everyday life  Obstacles in planning or solving problems  Difficulty in understanding visual pictures and partial relationships  New issues with phrases in talking or writing  Reduced or poorly judged  losing the ability to retrace steps and Misplacing Things  Withdrawal from job or social activities  Difficulty in finishing familiar duties at home And at job or at leisure  Changes in state of mind and character</p>
<p>III. DATABASES</p>
<p>A. ADNI Database: ANDI [21] database having from known patient's data for Alzheimer's disease (AD) patients and the no disease patient's data and mild congestive implement (MIC) patients all information is there in the database. it mainly consider by the values are observed by the so many patients details of taken by the age, gender, education etc...In this database used to known the patient having Alzheimer's disease (AD) or not.</p>
<p>B. OASIS Database:</p>
<p>The Open Access Series of Imaging Studies (OASIS) [19] is originates from Dr. R. Buckner which enables free availability of the brain MRI data sets available to the research community. The OASIS dataset contains two categories of data a) Cross-sectional MRI data b) Longitudinal MRI data of demented and non-demented elderly adults [25]. In this paper we use OASIS Dataset for studying the Alzheimer's dieses. This set is a cross-sectional compilation of 416 subjects between the ages of 18 and 96. Three or four person T1-weighted MRI scans are included for each subject acquired in single scan sessions. The subjects are all right-handed, including males and females alike. Clinically, 100 of the subjects over the era of 60 were diagnosed with Alzheimer's disease (AD) very mild to moderate.</p>
<p>IV. MACHINE LEARNING STRATEGIES</p>
<p>"Machine learning is a data analysis technique that Automates the construction of analytical models.</p>
<p>It is a division of artificial intelligence based on the concept that, with minimal human interference, systems can learn from data, identify patterns and make decisions." ML is categorised into Supervised and Unsupervised these techniques are used to study of AD.</p>
<p>Figure 1: Machine Learning Techniques</p>
<p>A. Supervised Learning:</p>
<p>The supervised learning concept is constructed on a supervisor, teaches the learning Model to Use the trainingdata set to reference unlabeled data to a clas s label [17], In this model provide the both input and desired output and mapped between them Mapped is based on the data features acquired. Support vector Machine: "Support Vector Machine (SVM)" is a supervised algorithm for machine learning, used to solve the problems of classification and regression, the objective of SVM is to identify the ideal hyper plane for two classes between the training data. Kernel characteristics can be Use dto map the training set to a highlevel function space from i nput space.</p>
<p>Logistic Regression: Logistic Regression [17] is a supervised Machine Learning algorithm, it is used to solve the classification problems; LR Regression estimates the relationship between the dependent and two or more independent variables by estimating the probabilities using the Logistic function or also called Sigmoid function defined as Where Xi is the independent variable bi is The coefficients to be estimated in logistical regression by the fitting model.</p>
<p>In many AD research, LRC was used to justify discrimination against AD from other dementia types, early diagnosis, and AD progression.</p>
<p>B. Unsupervised Learning:</p>
<p>In Unsupervised Learning separate objects in various groups, no supervisor is provided i.e. no training data is available to use. Unsupervised Learning validates a mapping function to discover masked patterns and comparisons from unlabeled input datasets K-Mean: K-means clustering is unsupervised Machine learning strategy for grouping objects in a predefined set of K clusters. The process of K-Mean start with random center in data which are used as the beginning points for every cluster, and then tries to attach the nearest points to these canters. In several AD studies, K-means are used to cluster brain tissue, hippocampal and tumor segmentations.</p>
<p>V. LITERATURE SURVEY ON CLASSIFICATION TECHNIQUES FOR ALZHEIMER'S DISEASE DETECTION</p>
<p>In Table I, Table II and Table III </p>
<p>VI. PROCEDURE FOR CLASSIFICATION</p>
<p>The detail procedure of Classification of Brain MRI Images using machine Learning Techniques given in the below figure 2.</p>
<p>In first stage is Pre processing, it is an improvement of image data that suppresses the redundant and Unobtrusive distortions from image or enhance image features, different image pre processing techniques like linearization, Resizing, Thresholding, Normalization used in Study of AD.</p>
<p>In stage2 perform the image segmentation is a process of dividing image into various parts, the objective is change representation of image and faster to analyze, Segmentation of images used in numerous AD research, Sukanta Ghosh et al [15] Proposed a Fuzzy logic-based segmentation algorithm to solve the object Border detection of brain images, its topology-based algorithm is implemented with a novel Fuzzy rule-base and FIS targeted at detecting strong and weak edges of brain MRI images. The algorithm is helpful to early detection of AD by accurately identifying the of objects boundaries and tracing of abnormal tissue losses. The described fuzzy algorithm can be associated with a deep learning technique.</p>
<p>Figure2: Classification process</p>
<p>Yeliz Karaca et.al [16] implemented "Automatic RGB Color Segment Score Algorithm" It is an decision-making method that can be helpful for the diagnosis of brain MRI by decision rules. The technique implemented in 3 stages in stage 1 is Pre processing, to extract the brain from the MRI on a gray scale of AD, perform dilation and erosion morphological Operations. Stage2 is RGB segmentation stage, RGB values for color segmentation of threshold value (μi &gt; 15 pixels) has been defined using Otsu's technique through multi-level thresholding. Stage3 Post-processing stage: By implementing the CART algorithm, the decision rules are acquired dilation and erosion was chosen from the morphological image processing techniques. Stage 3 is One of the significant step in the AD diagnosis is feature extraction and Selection. It extracts specific features from pre processed image of different abnormal categories [ 18] , It's technique of decrease the original data by evaluating certain important characteristics of image. Different types of features used to diagnosis of AD like Structural features [8], wavelet based, Texture Features [9,12], volumetric feature [13], histogram based, color based, shape based, GLCM based from Brain MRI. In the classification stage it try to classify image based on their properties and assign a class label for the feature set. The classifiers into two categorized one is Binary classifiers ,other is Multi-Class classifiers ,In Binary classifier Classification with only 2 distinct classes or with 2 pre defined possible outcomes either presence or absence of abnormalities of brain image, Multi-Class classifiers is Classification with more than two distinct classes. In the Study of AD various classification methods are use like Support Vector Machine [7,10,13], convolution neural network [11], DNN [12], ANN [14], Decision tree, Naive Bayes K-nearest neighbor, Fuzzy methods are so useful to early detection of Alzheimer's detection.</p>
<p>The data set is divided into parts that are train and test data sets. Training data is used to calculate the patterns inherent the same. Testing is performed, and then observed if the patterns are in spot. For training and testing, similar data are required, generally extracted from same data set.</p>
<p>In the end, we have a anticipated disease based on the distinct algorithms with a final result of a disease predicted depending with certain symptoms of input.</p>
<p>A. Evaluation Metrics:</p>
<p>Evaluation metrics plays a significant role to discriminate among various machine learning models. We use Accuracy, Sensitivity and Specificity metrics to evaluate the performance of the Classifier.</p>
<p>Accuracy: Accuracy is one of the best metric to evaluating the performance of any classification method.</p>
<p>"Accuracy is the ratio of number of correct predictions to the total number of input samples."</p>
<p>By using the below formula we will calculate the Accuracy of any classifier.</p>
<p>Sensitivity:</p>
<p>Sensitivity (also called the True Positive Rate) is defined as the proportion of actual positives, which got predicted as the Positive, by considering all positive data points. </p>
<p>Specificity:</p>
<p>Specificity is defined is the proportion of true negative data points that are correctly considered as negative, by considering all negative data points.</p>
<p>Results:</p>
<p>In the table horizontally all the classifiers are mentioned and vertically all the performance Metrics mentioned on the basis of these parameters we can Conclude the best approach to identify the Alzheimer's disease. All the above mentioned parameters in the table are derived by using WEKA tool. In the below graph we took classification methods in the X-Axis, it Represents Accuracy, Sensitivity and Specificity of each classifier, the vales of Accuracy, Sensitivity and Specificity can be measured based the above said formula. Based on the observations the accuracy of SVM is 97.6 % .When Compare to the remaining classifiers SVM gives best performance  This article provided an extensive overview of Predication of Alzheimer's disease by using different machine learning based methods, also provided the process of classification of Brain images and a summary of the results acquired by various researchers to predict Alzheimer's disease. As recognized from the literature research, much research has been done in early detection of Alzheimer's disease, but the crucial need remains to identify Appropriate features that could detect Alzheimer are at an early stage .This article also provide various classifier and its performance evaluation on different metrics and finally concluded that SVM gives better results than other classifier.</p>
<p>Future research encompasses extracting reasonable set of features for early identification of Alzheimer's disease and also to decrease the insignificant and redundant conventional feature sets to enhance Alzheimer's methods effectively. . </p>
<p>Figure 3 :
3Comparison of various ClassifiersCONCLUSION:</p>
<p>includes summary of various research articles of 2019,2018,2017 years for Classification techniques for early Alzheimer's disease Detection ,it cohere which type of classifier , data source ,type of features are extracted and outcome of the research.International Journal of Engineering and Advanced Technology (IJEAT) 
ISSN: 2249 -8958, Volume-8 Issue-6, August 2019 </p>
<p>5208 </p>
<p>Published By: 
Blue Eyes Intelligence Engineering 
&amp; Sciences Publication </p>
<p>Retrieval Number F8215088619/2019©BEIESP 
DOI: 10.35940/ijeat.F8215.088619 </p>
<p>Table I :
ISummary of Classification approaches of Alzheimer's disease Diagnosis of 2017</p>
<p>Table II :
IISummary of Classification approaches of Alzheimer's disease Diagnosis of 2018</p>
<p>Table III :
IIISummary of Classification approaches of Alzheimer's disease Diagnosis of 2019Exploring of Classification Methods for Early Detection of Alzheimer's Disease </p>
<p>5209 </p>
<p>Published By: 
Blue Eyes Intelligence Engineering 
&amp; Sciences Publication </p>
<p>Retrieval Number F8215088619/2019©BEIESP 
DOI: 10.35940/ijeat.F8215.088619 </p>
<p>Table IV :
IVperformance metrics of various classifiers CLASSIFIER TP RATE FP RATE PRECISION RECALL F-MEASURE MCCROC 
AREA </p>
<p>PRC 
AREA </p>
<p>NAIVE 
BAYES 
0.914 
0.053 
0.909 
0.914 
0.911 
0.868 
0.978 
0.944 </p>
<p>LOGISTIC 
0.93 
0.06 
0.935 
0.93 
0.916 
0.89 
0.986 
0.973 </p>
<p>SVM 
0.976 
0.021 
0.976 
0.976 
0.975 
0.961 
0.979 
0.958 </p>
<p>RANDOM 
FOREST 
0.954 
0.04 
0.957 
0.954 
0.948 
0.93 
0.999 
0.995 </p>
<p>An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning. F Razavi, M J Tarokh, M Alborzi, Journal of Big Data. 6132Razavi, F., Tarokh, M. J., &amp; Alborzi, M. (2019). An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning. Journal of Big Data, 6(1), 32.</p>
<p>Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors. Y Varatharajah, V K Ramanan, R Iyer, P Vemuri, Cognitive Resilience, and Demographics. Scientific reports. 912235Varatharajah, Y., Ramanan, V. K., Iyer, R., &amp; Vemuri, P. (2019). Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. Scientific reports, 9(1), 2235.</p>
<p>Predicting Alzheimer's disease progression using multi-modal deep learning approach. G Lee, K Nho, B Kang, K A Sohn, D Kim, Scientific reports. 911952Lee, G., Nho, K., Kang, B., Sohn, K. A., &amp; Kim, D. (2019). Predicting Alzheimer's disease progression using multi-modal deep learning approach. Scientific reports, 9(1), 1952.</p>
<p>Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. R B Mofrad, N S Schoonenboom, B M Tijms, P Scheltens, P J Visser, W M Van Der Flier, C E Teunissen, Assessment &amp; Disease Monitoring. 11Alzheimer's &amp; Dementia: DiagnosisMofrad, R. B., Schoonenboom, N. S., Tijms, B. M., Scheltens, P., Visser, P. J., van der Flier, W. M., &amp; Teunissen, C. E. (2019). Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring, 11, 1-9.</p>
<p>k-Skip-n-Gram-RF: A Random Forest Based Method for Alzheimer's Disease Protein Identification. L Xu, G Liang, C Liao, G D Chen, C C Chang, Frontiers in genetics. 10Xu, L., Liang, G., Liao, C., Chen, G. D., &amp; Chang, C. C. (2019). k-Skip-n-Gram-RF: A Random Forest Based Method for Alzheimer's Disease Protein Identification. Frontiers in genetics, 10.</p>
<p>Multi-stream multi-scale deep convolutional networks for Alzheimer's disease detection using MR images. C Ge, Q Qu, I Y H Gu, A S Jakola, 10.35940/ijeat.F8215.088619Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619. 350Ge, C., Qu, Q., Gu, I. Y. H., &amp; Jakola, A. S. (2019). Multi-stream multi-scale deep convolutional networks for Alzheimer's disease detection using MR images. Neurocomputing, 350, 60-69. Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619/2019©BEIESP DOI: 10.35940/ijeat.F8215.088619</p>
<p>An improved machine learning technique based on downsized KPCA for Alzheimer's disease classification. S Neffati, K Ben Abdellafou, I Jaffel, O Taouali, K Bouzrara, International Journal of Imaging Systems and Technology. 292Neffati, S., Ben Abdellafou, K., Jaffel, I., Taouali, O., &amp; Bouzrara, K. (2019). An improved machine learning technique based on downsized KPCA for Alzheimer's disease classification. International Journal of Imaging Systems and Technology, 29(2), 121-131.</p>
<p>A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain. Y Ding, J H Sohn, M G Kawczynski, H Trivedi, R Harnish, N W Jenkins, . . Behr, S C , Radiology. 2902Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., ... &amp; Behr, S. C. (2018). A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain. Radiology, 290(2), 456-464.</p>
<p>Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. J Islam, Y Zhang, Brain informatics. 52Islam, J., &amp; Zhang, Y. (2018). Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. Brain informatics, 5(2), 2.</p>
<p>Early Diagnosis of Alzheimer's Disease from MRI Images Using PNN. N A Mathew, R S Vivek, P R Anurenjan, 2018 International CET Conference on Control, Communication, and Computing (IC4). IEEEMathew, N. A., Vivek, R. S., &amp; Anurenjan, P. R. (2018, July). Early Diagnosis of Alzheimer's Disease from MRI Images Using PNN. In 2018 International CET Conference on Control, Communication, and Computing (IC4) (pp. 161-164). IEEE.</p>
<p>Classification of Alzheimer's disease based on eight-layer convolutional neural network with leaky rectified linear unit and max pooling. S H Wang, P Phillips, Y Sui, B Liu, M Yang, H Cheng, Journal of medical systems. 42585Wang, S. H., Phillips, P., Sui, Y., Liu, B., Yang, M., &amp; Cheng, H. (2018). Classification of Alzheimer's disease based on eight-layer convolutional neural network with leaky rectified linear unit and max pooling. Journal of medical systems, 42(5), 85.</p>
<p>Deep Neural Network Classification method to Alzheimer" s Disease Detection. K K Gulhare, S P Shukla, L K Sharma, International Journals of Advanced Research in Computer Science and Software Engineering. 7Gulhare, K. K., Shukla, S. P., &amp; Sharma, L. K. Deep Neural Network Classification method to Alzheimer" s Disease Detection. International Journals of Advanced Research in Computer Science and Software Engineering ISSN: 2277-128X (Volume-7, Issue-6)</p>
<p>Alzheimer disease classification using KPCA, LDA, and multi-kernel learning SVM. S Alam, G R Kwon, International Journal of Imaging Systems and Technology. 272Alzheimer's Disease Neuroimaging InitiativeAlam, S., Kwon, G. R., &amp; Alzheimer's Disease Neuroimaging Initiative. (2017). Alzheimer disease classification using KPCA, LDA, and multi-kernel learning SVM. International Journal of Imaging Systems and Technology, 27(2), 133-143.</p>
<p>A machine learning based approach for detection of alzheimer's disease using analysis of hippocampus region from MRI scan. A Raut, V Dalal, 2017 International Conference on Computing Methodologies and Communication (ICCMC). IEEERaut, A., &amp; Dalal, V. (2017, July). A machine learning based approach for detection of alzheimer's disease using analysis of hippocampus region from MRI scan. In 2017 International Conference on Computing Methodologies and Communication (ICCMC) (pp. 236-242). IEEE.</p>
<p>A novel fuzzy pixel intensity correlation based segmentation algorithm for early detection of Alzheimer's disease. Sukanta Ghosh, Abhijit Chandrarajani, K Mudi, Multimedia Tools and Applications. Sukanta Ghosh , Abhijit ChandraRajani, K. Mudi," A novel fuzzy pixel intensity correlation based segmentation algorithm for early detection of Alzheimer's disease", Multimedia Tools and Applications,2018</p>
<p>Gini Based Learning for the Classification of Alzheimer's Disease and Features Identification with Automatic RGB Segmentation Algorithm. Yeliz Karaca, Majaz Moonis, Abul Hasan Siddiqi, Ba¸sar Turan, ICCSA 2018. 10961Yeliz Karaca , Majaz Moonis, Abul Hasan Siddiqi, and Ba¸sar Turan,"Gini Based Learning for the Classification of Alzheimer's Disease and Features Identification with Automatic RGB Segmentation Algorithm.": ICCSA 2018, LNCS 10961, pp. 92-106, 2018</p>
<p>Imaging and machine learning techniques for diagnosis of Alzheimer's disease. G Mirzaei, A Adeli, H Adeli, Reviews in the Neurosciences. 278Mirzaei, G., Adeli, A., &amp; Adeli, H. (2016). Imaging and machine learning techniques for diagnosis of Alzheimer's disease. Reviews in the Neurosciences, 27(8), 857-870.</p>
<p>Rashmi Patange A Survey on Classification Methods of Brain MRI for Alzheimer's Disease. Mamata Lohar, International Journal of Engineering Research &amp; Technology (IJERT). 705Mamata Lohar., Rashmi Patange A Survey on Classification Methods of Brain MRI for Alzheimer's Disease. International Journal of Engineering Research &amp; Technology (IJERT) ISSN: 2278-0181 Vol. 7 Issue 05, May-2018</p>
<p>. A Alzheimer&apos;s, Alzheimer's, A. (2015). 2015</p>
<p>Alzheimer's &amp; dementia: the journal of the. Alzheimer's Association. 113332Alzheimer's disease facts and figuresAlzheimer's disease facts and figures. Alzheimer's &amp; dementia: the journal of the Alzheimer's Association, 11(3), 332.</p>
<p>Alzheimer's Association. 2017Alzheimer's Association. (2017). 2017</p>
<p>Alzheimer's disease facts and figures. 13Alzheimer's &amp; DementiaAlzheimer's disease facts and figures. Alzheimer's &amp; Dementia, 13(4), 325-373.</p>
<p>The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. K Antila, J Lötjönen, L Thurfjell, J Laine, M Massimini, D Rueckert, . . Hviid Simonsen, A , Interface Focus. 32Antila, K., Lötjönen, J., Thurfjell, L., Laine, J., Massimini, M., Rueckert, D., ... &amp; Hviid Simonsen, A. (2013). The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus, 3(2), 20120072.</p>
<p>Comparative analysis of various machine learning algorithms for detecting dementia. D Bansal, R Chhikara, K Khanna, P Gupta, Procedia computer science. 132Bansal, D., Chhikara, R., Khanna, K., &amp; Gupta, P. (2018). Comparative analysis of various machine learning algorithms for detecting dementia. Procedia computer science, 132, 1497-1502.</p>            </div>
        </div>

    </div>
</body>
</html>